(CDLX) Cardlytics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14161W1053
CDLX: Advertising, Analytics, Data, Marketing, Platform
Cardlytics, Inc. (NASDAQ:CDLX) is a leading provider of advertising and customer data platforms, operating primarily in the United States and the United Kingdom. The company’s core offering includes the Cardlytics platform, a proprietary native bank advertising channel that connects marketers with consumers through partnerships with financial institutions. This platform leverages digital channels such as online banking, mobile applications, email, and real-time notifications to deliver targeted advertisements. Additionally, the Bridg platform serves as a customer data platform that utilizes point-of-sale data to enable advanced analytics, targeted loyalty marketing, and measurable marketing impact analysis. Founded in 2008 and headquartered in Atlanta, Georgia, Cardlytics has established itself as a key player in the advertising technology space. Web URL: https://www.cardlytics.com
From a technical perspective, CDLX is showing a declining trend, with its SMA 20 and SMA 50 below the SMA 200, indicating bearish momentum. The stock is trading at $2.44 with an average volume of 884,119 shares over the past 20 days. The ATR of 0.27 suggests moderate volatility. On the fundamental side, the company has a market cap of $136.71 million, with a price-to-book ratio of 2.16 and a price-to-sales ratio of 0.47, indicating a potentially undervalued stock relative to its peers.
3-Month Forecast (Based on Technical and Fundamental Data): - Technical Outlook: CDLX is expected to remain under pressure as the SMA 20 and SMA 50 continue to trend below the SMA 200. Support levels may be tested near $2.00, with resistance at $3.50. The ATR of 0.27 suggests that price fluctuations will remain moderate. - Fundamental Outlook: The company’s focus on enhancing its customer data platform (Bridg) and expanding its financial institution partnerships could drive incremental revenue growth. However, the absence of positive P/E ratios and the lack of return on equity (RoE) may weigh on investor sentiment. Overall, the stock is likely to trade in a range-bound manner with limited upside potential in the near term.Additional Sources for CDLX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CDLX Stock Overview
Market Cap in USD | 77m |
Sector | Communication Services |
Industry | Advertising Agencies |
GiC Sub-Industry | Advertising |
IPO / Inception | 2018-02-09 |
CDLX Stock Ratings
Growth Rating | -93.4 |
Fundamental | -15.3 |
Dividend Rating | 0.0 |
Rel. Strength | -88.9 |
Analysts | 2.83/5 |
Fair Price Momentum | 0.97 USD |
Fair Price DCF | - |
CDLX Dividends
No Dividends PaidCDLX Growth Ratios
Growth Correlation 3m | -92.8% |
Growth Correlation 12m | -87.5% |
Growth Correlation 5y | -85.4% |
CAGR 5y | -49.15% |
CAGR/Max DD 5y | -0.50 |
Sharpe Ratio 12m | -0.59 |
Alpha | -97.34 |
Beta | 2.259 |
Volatility | 115.77% |
Current Volume | 1187.5k |
Average Volume 20d | 791.5k |
As of April 19, 2025, the stock is trading at USD 1.50 with a total of 1,187,526 shares traded.
Over the past week, the price has changed by +1.35%, over one month by -36.17%, over three months by -55.88% and over the past year by -87.44%.
Neither. Based on ValueRay Fundamental Analyses, Cardlytics is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -15.31 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDLX as of April 2025 is 0.97. This means that CDLX is currently overvalued and has a potential downside of -35.33%.
Cardlytics has received a consensus analysts rating of 2.83. Therefor, it is recommend to hold CDLX.
- Strong Buy: 0
- Buy: 0
- Hold: 5
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, CDLX Cardlytics will be worth about 1.1 in April 2026. The stock is currently trading at 1.50. This means that the stock has a potential downside of -30%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.3 | 120% |
Analysts Target Price | 4.4 | 193.3% |
ValueRay Target Price | 1.1 | -30% |